全文获取类型
收费全文 | 46204篇 |
免费 | 3053篇 |
国内免费 | 342篇 |
专业分类
耳鼻咽喉 | 172篇 |
儿科学 | 1189篇 |
妇产科学 | 1224篇 |
基础医学 | 3950篇 |
口腔科学 | 2070篇 |
临床医学 | 3954篇 |
内科学 | 9309篇 |
皮肤病学 | 532篇 |
神经病学 | 2425篇 |
特种医学 | 1098篇 |
外科学 | 4200篇 |
综合类 | 1560篇 |
一般理论 | 4篇 |
预防医学 | 11369篇 |
眼科学 | 562篇 |
药学 | 2167篇 |
1篇 | |
中国医学 | 133篇 |
肿瘤学 | 3680篇 |
出版年
2024年 | 38篇 |
2023年 | 1444篇 |
2022年 | 2123篇 |
2021年 | 2340篇 |
2020年 | 2616篇 |
2019年 | 1784篇 |
2018年 | 1792篇 |
2017年 | 1903篇 |
2016年 | 1910篇 |
2015年 | 1841篇 |
2014年 | 3338篇 |
2013年 | 3131篇 |
2012年 | 2154篇 |
2011年 | 2074篇 |
2010年 | 2312篇 |
2009年 | 2157篇 |
2008年 | 1543篇 |
2007年 | 1646篇 |
2006年 | 1485篇 |
2005年 | 1261篇 |
2004年 | 1038篇 |
2003年 | 1060篇 |
2002年 | 1015篇 |
2001年 | 935篇 |
2000年 | 904篇 |
1999年 | 789篇 |
1998年 | 427篇 |
1997年 | 409篇 |
1996年 | 366篇 |
1995年 | 300篇 |
1994年 | 242篇 |
1993年 | 184篇 |
1992年 | 386篇 |
1991年 | 366篇 |
1990年 | 382篇 |
1989年 | 293篇 |
1988年 | 295篇 |
1987年 | 143篇 |
1986年 | 43篇 |
1985年 | 111篇 |
1984年 | 96篇 |
1983年 | 90篇 |
1982年 | 80篇 |
1981年 | 73篇 |
1980年 | 58篇 |
1979年 | 71篇 |
1978年 | 46篇 |
1977年 | 45篇 |
1976年 | 37篇 |
1974年 | 49篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
11.
12.
《HPB : the official journal of the International Hepato Pancreato Biliary Association》2022,24(8):1201-1216
BackgroundPancreatic ductal adenocarcinoma (PDAC) has poor survival. Current treatments offer little likelihood of cure or long-term survival. This systematic review evaluates prognostic models predicting overall survival in patients diagnosed with PDAC.MethodsWe conducted a comprehensive search of eight electronic databases from their date of inception through to December 2019. Studies that published models predicting survival in patients with PDAC were identified.Results3297 studies were identified; 187 full-text articles were retrieved and 54 studies of 49 unique prognostic models were included. Of these, 28 (57.1%) were conducted in patients with advanced disease, 17 (34.7%) with resectable disease, and four (8.2%) in all patients. 34 (69.4%) models were validated, and 35 (71.4%) reported model discrimination, with only five models reporting values >0.70 in both derivation and validation cohorts. Many (n = 27) had a moderate to high risk of bias and most (n = 33) were developed using retrospective data. No variables were unanimously found to be predictive of survival when included in more than one study.ConclusionMost prognostic models were developed using retrospective data and performed poorly. Future research should validate instruments performing well locally in international cohorts and investigate other potential predictors of survival. 相似文献
13.
《European journal of medical genetics》2021,64(12):104345
BackgroundEpidermolysis bullosa (EB) is a genodermatosis characterized by skin fragility and blisters with variable severity. Patients with Dystrophic EB (DEB) or Junctional EB (JEB) mainly present to clinic due to greater functional impairment. Pathogenic sequence variations in COL7A1 are implicated in DEB.ObjectiveWe have tried to decipher the molecular spectrum and genotype phenotype correlation of 21 Indian patients with EB.MethodsNext generation sequencing (NGS) was performed to determine the pathogenic variants. Sanger sequencing was also done for validation of the variants in eleven individuals.ResultsPathogenic variants were detected in 20 individuals (diagnostic yield of 95%). Majority of them (90%) had sequence variation in COL7A1 while two had pathogenic variants in ITGB4 and KRT14 respectively. Out of the 18 patients confirmed to have DEB, 3 had Dominant DEB (DDEB) whereas 15 patients had Recessive DEB (RDEB). Amongst 23 sequence variations identified, 12 were found to be novel (3 were missense, 5 were premature termination codon variants while 4 were splice-site changes).ConclusionGenotype phenotype correlation was noted with milder manifestations in those with dominant inheritance types. Exact molecular diagnosis can be ascertained by NGS in majority of cases. 相似文献
14.
《Journal of clinical lipidology》2021,15(4):540-544
Cerebrotendinous xanthomatosis (CTX), sitosterolemia, and Smith-Lemli Opitz syndrome (SLOS) are rare inborn errors of metabolism. The diagnoses of CTX and sitosterolemia are often delayed for many years because of lack of physician awareness, often resulting in significant and unnecessary progression of disease. CTX may present with chronic diarrhea, juvenile onset cataracts, strikingly large xanthomas, and neurologic disease in the setting of a normal serum cholesterol, but markedly elevated serum or plasma cholestanol levels. These patients have a defect in producing the bile acid chenodoxycholate, and oral chenodeoxycholate therapy is essential for these patients in order to prevent neurologic complications. Sitosterolemia can present with xanthomas, anemia, thrombocytopenia, splenomegaly, very premature heart disease, and serum cholesterol levels that may be normal or elevated, along with marked elevations of plasma β-sitosterol. These patients have a defect causing overabsorption of β-sitosterol, and the treatment of choice is oral ezetimibe. SLOS presents with growth delay, intellectual disability, multiple structural anomalies, and low serum cholesterol levels, and the defect is reduced cholesterol production. Treatment consists of dietary cholesterol supplementation and oral bile acid therapy which raises serum cholesterol levels and may improve symptoms. The metabolic and genetic defects in these disorders have been defined. There is no one in our field that has contributed more to the diagnosis and treatment of these disorders than Gerald Salen, MD, who died in late 2020 at 85 years of age. He will be greatly missed by his family, friends, and colleagues from around the world. 相似文献
15.
16.
17.
18.
19.
《Clinical therapeutics》2022,44(7):1012-1025
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are the mainstay of treatment for hypercholesterolemia as they effectively reduce LDL-C levels and risk of atherosclerotic cardiovascular disease. Apart from hyperglycemia, dyslipidemia and HDL dysfunction are known risk factors for neuropathy in people with obesity and diabetes. Although there are case reports of statin-induced neuropathy, ad hoc analyses of clinical trials and observational studies have shown that statins may improve peripheral neuropathy. However, large randomized controlled trials and meta-analyses of cardiovascular outcome trials with statins and other lipid-lowering drugs have not reported on neuropathy outcomes. Because neuropathy was not a prespecified outcome in major cardiovascular trials, one cannot conclude whether statins or other lipid-lowering therapies increase or decrease the risk of neuropathy. The aim of this review was to assess if statins have beneficial or detrimental effects on neuropathy and whether there is a need for large well-powered interventional studies using objective neuropathy end points. 相似文献
20.
《Journal of diabetes and its complications》2022,36(12):108340
Diabetes mellitus is the leading disorder and affects more than millions of people worldwide. Nowadays, the usage of herbal drugs is said to control adiposity and hyperglycemia. The current research investigated the anti-adiposity and antidiabetic activity of S. saman leaf extract and bioactive compounds. Therefore, the results lower the sugar absorption into the blood and reveal the extract's antidiabetic properties. STZ-induced diabetic rats, Samanea saman methanolic extract show improvement in the parameters like fasting blood glucose levels, body weight, other biochemical parameters supported by the histopathological analysis, and an increase in serum levels in the experimental groups. The antioxidant plays a vital role by increasing SOD and catalase activity levels and decreasing lipid peroxidation levels. The methanolic extract protects the tissue from oxidation stress, which is responsible for the glycemic properties. According to the findings, diabetic-treated rats had overnight blood glucose levels lower and near standard biochemical markers. Histopathology of the liver, pancreas, kidneys, and adipose tissues supported the pharmacological observations.Further, we screened and documented S. saman extract used for in vitro and in vivo methods. In terms of effectiveness, the crude extracts exhibit 0.8-fold GLUT4 down-regulation. Consequently, this result contributes to clinical trials and develops antidiabetic therapy as a substitute for synthetic pharmaceuticals. 相似文献